In today’s NewsFlash Roundup, General Dynamics gets $10 million for grenade launchers and AMAG’s kidney drug gets FDA approval.

• Boston life science center pulls in $350M loan

The center, which is intended to serve as a world-class research and collaboration hub for life sciences companies and the Harvard University-affiliated teaching hospitals, was completed last year. As of the beginning of 2009, the center was nearing its capacity.

• AMAG wins FDA approval for kidney drug

AMAG Pharmaceuticals Inc. has won U.S. Food and Drug Administration approval for its drug, called Feraheme, to treat chronic kidney disease. The Lexington-based company’s drug is an injection designed to be used as an iron replacement therapy to fight anemia in patients with kidney disease. The drug can be used by patients who are on or off dialysis.

• DOE awards $750K to Marine Renewable Energy Center

The center’s Marine Renewable Energy Center will receive $750,000 from the U.S. Department of Energy’s fiscal year 2010 budget, said John Miller, director of operations for the ATMC and head of the marine center. The appropriation is on top of $1 million in DOE grant funding the marine center will receive to spur academic research efforts and support small marine technology companies. (more…)